Please assess the completion status of the following clinical trial:

Trial Title: CES1 Crossover Trial of Clopidogrel and Ticagrelor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Of Amish descent~* Age 18 to 75 years~* Participant in the Phamacogenomics of Anti-Platelet Intervention (PAPI-1) Study or other Amish Research Center study, or a family member of an Amish Research Center study participant.~Exclusion Criteria:~* Clopidogrel or ticagrelor allergy~* Platelet count \< 100,000 mm3 or \> 500,000 mm3~* Hematocrit (Hct) \< 32% or \> 50%~* Blood pressure \> 160/95 mm Hg~* Co-existing malignancy~* Creatinine \> 2.0 mg/dl~* Aspartate transaminase (AST) or alanine transaminase (ALT) \> 2 times the upper limit of normal~* Thyroid-stimulating hormone (TSH) \< 0.40 or \> 5.50 mU/L~* Pregnant or breast feeding~* History of gastrointestinal bleeding, a major life-threatening bleeding event, active pathological bleeding, bleeding diathesis, or coagulopathy~* History of stroke or transient ischemic attack, deep vein thrombosis, or atrial fibrillation~* History of myocardial infarction, coronary artery bypass surgery, unstable angina, or angioplasty~* History of sick sinus syndrome, 2nd or 3rd degree atrioventricular block, or bradycardia-related syncope~* Type 1 or Type 2 diabetes mellitus~* Surgery in the past 3 months or planned surgery in the next 3 months~* Participant cannot willingly and safely discontinue medications that, in the opinion of the study physician would affect the outcomes to be measured for at least 1 week prior to study initiation through completion of the study~* Participant is unwilling to discontinue taking vitamins and/or supplements that, in the opinion of the study physician would affect the outcomes to be measured for 1 week prior to the study initiation through the the completion of the study~* Any other condition that would place prospective participants at unacceptable risk or render them unable to meet the requirements of the protocol in the opinion of the site investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Wild-Type Genotype (Type: ACTIVE_COMPARATOR): Research subjects with wild type CES1 genotypes will be studied before and after oral ingestion of clopidogrel (75 mg/d for 8 days) and ticagrelor (90 mg twice daily for 8 days) treatment.
- Carriers of the CES1 G143E Mutation (Type: EXPERIMENTAL): Research subjects who carry the CES1 G143E allele (rs71647871) will be studied before and after oral ingestion of clopidogrel (75 mg/d for 8 days) and ticagrelor (90 mg twice daily for 8 days) treatment.
- Carriers of CES1 rs7498748 Mutation (Type: EXPERIMENTAL): Research subjects who carry a CES1 rs7498748 minor allele will be studied before and after oral ingestion of clopidogrel (75 mg/d for 8 days) and ticagrelor (90 mg twice daily for 8 days) treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).